Xgeva (Denosumab) Approved For Giant Cell Tumor Of The Bone Treatment, FDA

Xgeva (denosumab) has been approved by the U.S. FDA for the treatment of GCTB (giant cell tumor of the bone) in adults and skeletally mature adolescents. GCTB is a rare tumor which is usually non-cancerous. Giant cell tumor of the bone typically affects adults aged between 20 and 40 years. In the majority of cases, GCTB remains localized (does not spread). However, as it grows it destroys normal bone, resulting in severe pain, bone fractures and a limited range of motion. GCTB can become malignant and spread to the lungs, however this is rare...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Bones / Orthopedics Source Type: news